This study shows that hyper-acetylated HMGB1 is an accurate biomarker to differentiate malignant mesothelioma patients from individuals occupationally exposed to asbestos and unexposed controls. A trial to independently validate these findings will start soon.
Our multinational team discovered that four apparently unrelated US families share a common ancestor, a couple who immigrated from Germany in the early 1700s.
Online journal: Expert Review of Respiratory Medicine
Malignant mesothelioma is an aggressive cancer whose pathogenesis is causally linked to occupational exposure to asbestos. Familial clusters of mesotheliomas have been observed in settings of genetic predisposition. Mesothelioma incidence is anticipated to increase worldwide in the next two decades. Novel treatments are needed, as current treatment modalities may improve the quality of life, but have shown modest effects in improving overall survival. Increasing knowledge on the molecular characteristics of mesothelioma has led to the development of novel potential therapeutic strategies, including: molecular targeted approaches, that is the inhibition of vascular endothelial growth factor with bevacizumab; immunotherapy with chimeric monoclonal antibody, immunotoxin, antibody drug conjugate, vaccine and viruses; inhibition of asbestos-induced inflammation, that is aspirin inhibition of HMGB1 activity may decrease or delay mesothelioma onset and/or growth. We elaborate on the rationale behind new therapeutic strategies, and summarize available preclinical and clinical results, as well as efforts still ongoing.
Authors: Angela Bononi, Andrea Napolitano, Harvey I Pass, Haining Yang, and Michele Carbone
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression
Aspirin (acetylsalicylic acid, ASA) is the most widely used nonsteriodial anti-inflammatory drug that reduces the incidence, metastatic potential and mortality of many inflammation-induced cancers. Can it play a role in helping patients with malignant mesothelioma?
Remembering Dr. Baris's Influence on My Research
Dr. Baris, the former Director of Pulmonary Medicine at the University of Hacettepe, in Ankara, Turkey, had a profound influence on my life and work.